Clinical Trial Update: Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Pilot Phase 1/2 clinical trial evaluating anti-CD20 CAR-T cells in patients with chemotherapy-resistant or refractory B-cell lymphoma. The trial is sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Anti-CD20 CAR-T cells (CD20-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Beijing Biohealthcare Biotechnology Co.,Ltd | Conditions: Lymphoma, B-Cell | Phase 1, Phase 2 | Status: UNKNOWN